TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01916343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Laparoscopic Curriculum
Study: NCT04286815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lentiviral Vector Gene Therapy
Description: Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells
Study: NCT04397562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levilimab
Description: Levilimab 324 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02100969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIZENTRA ®
Description: Patients must fulfill inclusion criteria and remain stable at week 0, which means QMG does not increase by 3 points, will enter receive Hizentra for 12 weeks.
Study: NCT01629953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group vocational intervention
Description: Group based manualized vocational rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supported Employment Condition
Description: Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
Study: NCT01510743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization of subclavian vein
Description: Catheterization of subclavian vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheterization of internal jugular vein
Description: Catheterization of internal jugular vein
Study: NCT01504841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
Study: NCT01335269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 853520
Description: BI 853520 once daily in a dose escalation schedule
Study: NCT04483336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Virtual reality goggles are commercially available wearable devices that are used to view view videos and play video games three dimensionally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TV Screen Distraction
Description: A cartoon video was played on a regular TV screen.
Study: NCT00005085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Study: NCT03305978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra low dose chest CT
Description: An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose chest CT
Description: standard diagnostic low dose chest CT
Study: NCT03295773

Intervention type: DIAGNOSTIC_TEST
Intervention: 3DRA
Study: NCT02166268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVANZ Phleum pratense 15,000 SQ+

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02146638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study: NCT02146001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reducing sedentary behavior group
Description: This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-to-vigorous activity group
Description: This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
Study: NCT04090463

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy
Description: IORT will be delivered as follows:~1. Radical resection --\> delivery of 10-15 Gy to the tumor bed~2. Non radical resection --\> delivery of 15-20 Gy to the tumor in situ
Study: NCT01834079

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STEM CELL THERAPY
Description: Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
Study: NCT04776863

Intervention type: DEVICE
Intervention: optical biometry measurement
Description: The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.

Intervention type: DEVICE
Intervention: optical biometry measurement
Description: The measurements of the individuals using smokeless tobacco and those who do not were taken by optical biometry.
Study: NCT01484574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Single intramuscular administration of low dose of stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Single intramuscular administration of intermediate dose of stem cells
Study: NCT04366167

Intervention type: OTHER
Intervention: Cardiac surgery
Description: Cardiac surgery during the COVID-19 pandemic

Intervention type: OTHER
Intervention: Cardiac surgery
Description: Cardiac surgery during the COVID-19 pandemic

Intervention type: OTHER
Intervention: Cardiac surgery
Description: Cardiac surgery during the COVID-19 pandemic
Study: NCT01069133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg BID open-label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin
Description: 550mg PO BID
Study: NCT02853240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
Study: NCT04179253

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: office micro hysteroscopy
Description: One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
Study: NCT03846609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double balloon interventional platform (DiLumen)
Description: double balloon interventional platform (DiLumen) is used for removal of colonic polyp

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no double balloon interventional platform (DiLumen)
Description: double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
Study: NCT03853525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Description: Product is applied to one side of the inguinal region.
Study: NCT01616485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-1790
Description: 2 TA-1790 100 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: 2 sildenafil citrate 50 mg capsules
Study: NCT02783599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy
Study: NCT01616485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules for TA-1790 100 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrostat
Description: glyceryl trinitrate tablet, USP 0.4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrostat
Description: glyceryl trinitrate tablet, USP 0.4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrostat
Description: glyceryl trinitrate tablet, USP 0.4 mg
Study: NCT00772356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Spirit Insulin Pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator insulin pump
Study: NCT01810029

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation plus Transcendental Meditation
Description: The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation plus Transcendental Meditation
Description: The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
Study: NCT01280552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICT-107
Description: Autologous dendritic cells pulsed with immunogenic antigens
Study: NCT03853525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semisolid vaseline
Description: Product is applied to one side of the inguinal region.
Study: NCT01280552

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DC
Description: Autologous dendritic cells (DC) that have not been pulsed with antigens
Study: NCT03774589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Compressive Anastomosis
Description: The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Anastomosis
Description: A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
Study: NCT02522390

Intervention type: OTHER
Intervention: Research activities
Description: Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts.
Study: NCT04151290

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognoa ASD diagnostic device
Description: Cognoa device is intended to aid healthcare providers in diagnosing Autism Spectrum Disorder (ASD)
Study: NCT01411163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Up to 30 grams daily creatine monohydrate
Study: NCT00511693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: centralized osteoporosis coordinator
Description: The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: fall prevention
Description: Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
Study: NCT04636333

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Description: Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Description: Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
Study: NCT03496142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal prostate biopsy
Description: Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal prostate biopsy
Description: Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
Study: NCT01936116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonohysterography with inflated catheter in uterine cavity
Description: during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sonohysterography with inflated catheter in cervical cavity
Description: During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
Study: NCT00754754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Retraction Monitoring Sensor
Description: This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
Study: NCT00718328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Description: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
Study: NCT00199290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombination)
Study: NCT00709813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))
Description: Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
Study: NCT02908789

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Description: Selective caries removal + Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms + tooth restauration

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Without Antimicrobial phothodynamic therapy
Description: Selective caries removal + tooth restauration
Study: NCT00742729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: Educational small group session with free FOBT kit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Educational small group session with no FOBT kit
Study: NCT03853525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semisolid vaseline
Description: Product is applied to one side of the inguinal region.
Study: NCT02973035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Study: NCT00742729

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Arm 3
Description: Educational small group session, exercise
Study: NCT02479815

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Micronutrient Powder (MNP)
Description: Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
Study: NCT02286635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort and rifampin
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort and Clarithromycin
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
Study: NCT01474720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax vaccine
Description: Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zostavax vaccine
Description: Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
Study: NCT04623229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCS
Description: Manual Cataract Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReLACS Early
Description: ReLACS with early administration of anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReLACS Standard
Description: ReLACS with standard time administration of anesthesia
Study: NCT03224442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: soft tissue augmentation by prf

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal Pedicle
Description: soft tissue augmentation by palatal pedicle
Study: NCT05089773

Intervention type: PROCEDURE
Intervention: The arterial switch operation
Description: The ASO is a procedure that emerged as an anatomically as well as physiologically appropriate solution to the transposition of the great arteries. The aorta and pulmonary artery are detached from their native roots and reattached to the opposite root; thus, the pulmonary root becomes the neo-aorta, and the aortic root becomes the neo-pulmonary artery.~The coronary arteries are transplanted from the aorta/neo-pulmonary artery to the pulmonary artery/neo-aorta.